免疫疗法：高级别脊髓星形细胞瘤的一种潜在方法。
Immunotherapy: A Potential Approach for High-Grade Spinal Cord Astrocytomas.
机构信息
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
出版信息
Front Immunol. 2021 Feb 18;11:582828. doi: 10.3389/fimmu.2020.582828. eCollection 2020.
Abstract
Spinal cord astrocytomas (SCAs) account for 6-8% of all primary spinal cord tumors. For high-grade SCAs, the prognosis is often poor with conventional therapy, thus the urgent need for novel treatments to improve patient survival. Immunotherapy is a promising therapeutic strategy and has been used to treat cancer in recent years. Several clinical trials have evaluated immunotherapy for intracranial gliomas, providing evidence for immunotherapy-mediated ability to inhibit tumor growth. Given the unique microenvironment and molecular biology of the spinal cord, this review will offer new perspectives on moving toward the application of successful immunotherapy for SCAs based on the latest studies and literature. Furthermore, we will discuss the challenges associated with immunotherapy in SCAs, propose prospects for future research, and provide a periodic summary of the current state of immunotherapy for SCAs immunotherapy.
摘要
脊髓星形细胞瘤（SCA）占所有原发性脊髓肿瘤的 6-8%。对于高级别 SCA，传统治疗的预后往往较差，因此迫切需要新的治疗方法来提高患者的生存率。免疫疗法是一种很有前途的治疗策略，近年来已被用于治疗癌症。几项临床试验已经评估了免疫疗法治疗颅内神经胶质瘤，为免疫疗法介导抑制肿瘤生长的能力提供了证据。鉴于脊髓的独特微环境和分子生物学特性，本综述将根据最新的研究和文献，为将成功的免疫疗法应用于 SCA 提供新的视角。此外，我们还将讨论 SCA 免疫疗法相关的挑战，提出未来研究的前景，并定期总结 SCA 免疫疗法的现状。
相似文献
1
Immunotherapy: A Potential Approach for High-Grade Spinal Cord Astrocytomas.免疫疗法：高级别脊髓星形细胞瘤的一种潜在方法。
Front Immunol. 2021 Feb 18;11:582828. doi: 10.3389/fimmu.2020.582828. eCollection 2020.
2
Spinal cord astrocytomas: progresses in experimental and clinical investigations for developing recovery neurobiology-based novel therapies.脊髓星形细胞瘤：基于恢复神经生物学的新型治疗方法的实验和临床研究进展。
Exp Neurol. 2019 Jan;311:135-147. doi: 10.1016/j.expneurol.2018.09.010. Epub 2018 Sep 21.
3
The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation.脊髓胶质瘤有无 H3 K27M 突变的分子特征。
Acta Neuropathol Commun. 2020 Mar 30;8(1):40. doi: 10.1186/s40478-020-00913-w.
4
Current Immunotherapies for Glioblastoma Multiforme.目前用于多形性胶质母细胞瘤的免疫疗法。
Front Immunol. 2021 Mar 9;11:603911. doi: 10.3389/fimmu.2020.603911. eCollection 2020.
5
Immunotherapy for Glioblastoma: Current Progress and Challenges.胶质母细胞瘤的免疫治疗：现状与挑战。
Front Immunol. 2021 May 13;12:676301. doi: 10.3389/fimmu.2021.676301. eCollection 2021.
6
Understanding spinal cord astrocytoma: Molecular mechanism, therapy, and comprehensive management.了解脊髓星形细胞瘤：分子机制、治疗和综合管理。
Cancer Lett. 2024 Oct 1;601:217154. doi: 10.1016/j.canlet.2024.217154. Epub 2024 Aug 8.
7
GBM immunotherapy: Exploring molecular and clinical frontiers.GBM 免疫治疗：探索分子和临床前沿。
Life Sci. 2024 Nov 1;356:123018. doi: 10.1016/j.lfs.2024.123018. Epub 2024 Aug 28.
8
Towards a Systems Immunology Approach to Unravel Responses to Cancer Immunotherapy.朝着系统免疫学方法的方向，以揭示对癌症免疫疗法的反应。
Front Immunol. 2020 Oct 22;11:582744. doi: 10.3389/fimmu.2020.582744. eCollection 2020.
9
Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.溶瘤病毒联合癌症免疫治疗：开创新一代癌症治疗。
Front Immunol. 2020 Apr 28;11:683. doi: 10.3389/fimmu.2020.00683. eCollection 2020.
10
Prospects of biological and synthetic pharmacotherapies for glioblastoma.生物和合成药理学治疗胶质母细胞瘤的前景。
Expert Opin Biol Ther. 2020 Mar;20(3):305-317. doi: 10.1080/14712598.2020.1713085. Epub 2020 Jan 20.
引用本文的文献
1
Astrocyte Autophagy in Neurodegenerative Diseases: Current Progress in Mechanisms and Therapeutics.神经退行性疾病中的星形胶质细胞自噬：机制与治疗的当前进展
Neurochem Res. 2025 Sep 5;50(5):287. doi: 10.1007/s11064-025-04532-6.
2
Pooling umbilical cord-mesenchymal stromal cells derived from selected multiple donors reduces donor-dependent variability and improves their immunomodulatory properties.汇集来自多个选定供体的脐带间充质基质细胞可降低供体依赖性变异性并改善其免疫调节特性。
Stem Cell Res Ther. 2025 May 20;16(1):252. doi: 10.1186/s13287-025-04361-y.
3
Extracellular vesicles as therapeutic modulators of neuroinflammation in Alzheimer's disease: a focus on signaling mechanisms.细胞外囊泡作为阿尔茨海默病神经炎症的治疗调节剂：聚焦信号传导机制
J Neuroinflammation. 2025 Apr 25;22(1):120. doi: 10.1186/s12974-025-03443-1.
4
Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy.基于可溶性和细胞相关（免疫）标志物多重分析的乳腺癌评分有助于预测帕博利珠单抗治疗效果。
Cancer Cell Int. 2025 Mar 27;25(1):120. doi: 10.1186/s12935-025-03729-7.
5
Advances in Molecular Pathology, Diagnosis and Treatment of Spinal Cord Astrocytomas.脊髓星形细胞瘤的分子病理学、诊断和治疗进展。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241262483. doi: 10.1177/15330338241262483.
6
State-of-the-Art and New Treatment Approaches for Spinal Cord Tumors.脊髓肿瘤的最新技术与新治疗方法
Cancers (Basel). 2024 Jun 27;16(13):2360. doi: 10.3390/cancers16132360.
7
A Nomogram for Predicting Overall Survival of Patients With Primary Spinal Cord Glioblastoma.一种预测原发性脊髓胶质母细胞瘤患者总生存期的列线图。
Neurospine. 2024 Jun;21(2):676-689. doi: 10.14245/ns.2448082.041. Epub 2024 Jun 30.
8
Differential Cytokine Responses of APOE3 and APOE4 Blood-brain Barrier Cell Types to SARS-CoV-2 Spike Proteins.载脂蛋白 E3 和载脂蛋白 E4 血脑屏障细胞对 SARS-CoV-2 刺突蛋白的差异细胞因子反应。
J Neuroimmune Pharmacol. 2024 May 21;19(1):22. doi: 10.1007/s11481-024-10127-9.
9
An alternative extension of telomeres related prognostic model to predict survival in lower grade glioma.一种与端粒相关的预后模型的替代扩展，用于预测低级别胶质瘤的生存率。
J Cancer Res Clin Oncol. 2023 Nov;149(15):13575-13589. doi: 10.1007/s00432-023-05155-6. Epub 2023 Jul 29.
10
Unravelling the anti-inflammatory mechanism of Allium cepa: an integration of network pharmacology and molecular docking approaches.解析洋葱的抗炎机制：网络药理学和分子对接方法的整合。
Mol Divers. 2024 Apr;28(2):727-747. doi: 10.1007/s11030-023-10614-w. Epub 2023 Mar 3.
本文引用的文献
1
The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation.脊髓胶质瘤有无 H3 K27M 突变的分子特征。
Acta Neuropathol Commun. 2020 Mar 30;8(1):40. doi: 10.1186/s40478-020-00913-w.
2
T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.基于 T 细胞的疗法克服神经解剖和免疫抑制挑战在神经胶质瘤微环境中。
J Neurooncol. 2020 Apr;147(2):281-295. doi: 10.1007/s11060-020-03450-7. Epub 2020 Mar 17.
3
Brain immunology and immunotherapy in brain tumours.脑肿瘤的脑免疫学和免疫疗法。
Nat Rev Cancer. 2020 Jan;20(1):12-25. doi: 10.1038/s41568-019-0224-7. Epub 2019 Dec 5.
4
Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas.分析不同分子亚型弥漫性中线胶质瘤中 PD-L1 表达和 T 细胞浸润。
Neuropathology. 2019 Dec;39(6):413-424. doi: 10.1111/neup.12594. Epub 2019 Oct 17.
5
Towards Immunotherapy for Pediatric Brain Tumors.迈向小儿脑肿瘤的免疫治疗。
Trends Immunol. 2019 Aug;40(8):748-761. doi: 10.1016/j.it.2019.05.009. Epub 2019 Jun 19.
6
Spinal cord high-grade infiltrating gliomas in adults: clinico-pathological and molecular evaluation.成人脊髓高级别浸润性神经胶质瘤：临床病理和分子评估。
Mod Pathol. 2019 Sep;32(9):1236-1243. doi: 10.1038/s41379-019-0271-3. Epub 2019 Apr 26.
7
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.嵌合抗原受体修饰的 T 细胞过继转移治疗胶质母细胞瘤患者中针对 EGFRvIII 的初步临床试验
J Immunother. 2019 May;42(4):126-135. doi: 10.1097/CJI.0000000000000260.
8
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.新辅助抗 PD-1 免疫治疗在复发性胶质母细胞瘤中促进了肿瘤内和全身免疫应答，并带来生存获益。
Nat Med. 2019 Mar;25(3):477-486. doi: 10.1038/s41591-018-0337-7. Epub 2019 Feb 11.
9
Promising vaccines for treating glioblastoma.治疗脑胶质瘤有希望的疫苗。
Expert Opin Biol Ther. 2018 Nov;18(11):1159-1170. doi: 10.1080/14712598.2018.1531846. Epub 2018 Oct 15.
10
Chimeric Antigen Receptor Therapy.嵌合抗原受体疗法
N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169.
Zotero 插件